Alumis Inc.
ALMS
Hisse Senetlerindeki Sıralama
#9897
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Hisse Fiyatı
$6.78
Son senkronizasyon: 2026-10-21
Piyasa Değeri
$877.57M
Değişim (1 gün)
1.19%
Değişim (1 yıl)
198.68%
Ülke
US
Ticaret Alumis Inc. (ALMS)
Kategori
Healthcare
Alumis Inc. (ALMS) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $2.34 - 2025-05-01
Gün sonu en düşük fiyat: $21.58 - 2023-05-01
Gün sonu en düşük fiyat: $21.58 - 2023-05-01
Alumis Inc. için hisse fiyatı geçmişi: 2023 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2025 | -35.06% |
| 2024 | -49.49% |
| 2023 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.90 | -4.43% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
